Quoin Pharmaceuticals: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Quoin Pharmaceuticals (NASDAQ:QNRX) reported Q4 earnings, beating estimated EPS by 10.0% with an EPS of $-2.08 versus an estimate of $-2.31. However, revenue was unchanged from the same period last year. In the previous quarter, beating EPS estimates was followed by an 8.0% drop in share price the next day.
March 13, 2024 | 8:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Quoin Pharmaceuticals reported a better-than-expected Q4 EPS but with unchanged revenue from the previous year. Previous earnings beat led to a share price drop.
Despite beating EPS estimates, the lack of revenue growth and historical context of a share price drop following an earnings beat suggest a potential short-term negative impact on QNRX's stock price.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100